NEW YORK (GenomeWeb News) - Invitrogen’s share price jumped 10 percent today after the firm released third-quarter results that showed a double-digit increase in revenues and a swing from a loss to a profit.
The firm reported after the close of the market yesterday that its third-quarter revenues had spiked up 11 percent to $315 million and that last year’s losses had been turned to a $31 million profit.
The stock was up $8.34 at $91.41 in late afternoon trading today.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.